Adagene's Muzastotug Shows Enhanced Tumor Response at Higher Doses in Combination with Keytruda in Early Cancer Trial.

Adagene's experimental cancer drug, muzastotug, demonstrated improved tumor response at higher doses when combined with Merck's Keytruda in an early clinical trial. The Phase 1b/2 study showed that higher doses of muzastotug led to a better response when used in combination with pembrolizumab. The results suggest that Adagene's drug has potential in treating cancer.